In this study, we characterized the landscape of the TCRβ repertoire in tumor tissue from patients with stage II/III NSCLC with an EGFR mutation who received adjuvant therapy, including the TKI gefitinib and VP in the clinical trial (8). The gene discussed is EGFR; the disease is neoplasm.